gostatin: amino acid produced by Streptomyces sumanensis; time-dependent inhibitor of aspartate transaminase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 101100 |
| SCHEMBL ID | 11227814 |
| MeSH ID | M0124772 |
| Synonym |
|---|
| 5-amino-3-(carboxymethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2-carboxylic acid |
| 78416-84-9 |
| gostatin |
| nsc382261 |
| nsc-382261 |
| 5-amino-2-carboxy-4-oxo-1,4,5,6-tetrahydropyridine-3-acetic acid |
| 3-pyridineacetic acid, 5-amino-2-carboxy-1,4,5,6-tetrahydro-4-oxo-, (-)- |
| gostatine |
| nsc 382261 |
| unii-gnh8a5taq0 |
| gnh8a5taq0 , |
| SCHEMBL11227814 |
| 84986-74-3 |
| 3-pyridineacetic acid, 5-amino-2-carboxy-1,4,5,6-tetrahydro-4-oxo-, (-) |
| (-)-5-amino-2-carboxy-1,4,5,6-tetrahydro-4-oxo-3-pyridineacetic acid |
| Q27896951 |
| 3-pyridineacetic acid,5-amino-2-carboxy-1,4,5,6-tetrahydro-4-oxo- |
| SB78691 |
| 5-amino-3-(carboxymethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2-carboxylicacid |
| (-)-5-amino-3-(carboxymethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2-carboxylic acid |
Gostatin appears to be a relatively nonselective acidic amino acid antagonist in the mammalian central nervous system. Gostatin is a time-dependent inhibitor of the enzyme giving an enzyme half-life of 1.8 min.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Gostatin is a time-dependent inhibitor of the enzyme giving an enzyme half-life of 1.8 min at 3.1 microM (25 degrees C)." | ( Mechanism of inactivation of pyridoxal phosphate-linked aspartate transaminase by gostatin. Murao, S; Nishino, T; Wada, H, 1984) | 1.21 |
| "Gostatin appears to be a relatively nonselective acidic amino acid antagonist in the mammalian central nervous system." | ( Gostatin blocks physiological actions and binding of acidic amino acids in rat brain. Fagg, GE; Lanthorn, TH, 1989) | 2.44 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.14) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||